TAKEDA PHARMACEUTI SPON ADR EA REPR 0.5 ORD (TKPYY)

20.40
0.14 0.67
OTC
Prev Close 20.27
Open 20.72
Day Low/High 20.37 / 20.72
52 Wk Low/High 20.15 / 25.50
Volume 81.81K
Exchange OTC
Shares Outstanding 1580.69B
Market Cap 33.22B
Div & Yield N.A. (N.A)

Latest News

Valeant Plummets on Reports of Salix Takeover Breakdown

Valeant Plummets on Reports of Salix Takeover Breakdown

Valeant shares fell Wednesday on news that talks with Takeda to take over Valeant's Salix unit have broken down.

Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness And Safety In Inflammatory Bowel Disease In More Than 50 Real-World Studies

Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness And Safety In Inflammatory Bowel Disease In More Than 50 Real-World Studies

In patients with moderate to severely active ulcerative colitis or Crohn's disease, review of real-world data supports outcomes of vedolizumab clinical trial program

Buy These 4 Stocks and Beat Biotech's Slump

Buy These 4 Stocks and Beat Biotech's Slump

Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.

Additional Interim Data Supporting Long-Term Use Of Vedolizumab In Patients With Ulcerative Colitis And Crohn's Disease Published In Journal Of Crohn's And Colitis

Additional Interim Data Supporting Long-Term Use Of Vedolizumab In Patients With Ulcerative Colitis And Crohn's Disease Published In Journal Of Crohn's And Colitis

Interim analyses shows clinical benefits with long-term vedolizumab treatment regardless of prior tumor necrosis factor (TNF) antagonist exposure

Four Stellar Stocks to Beat the Biotech Slump

Four Stellar Stocks to Beat the Biotech Slump

Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum

Will Takeda Pharmaceutical (TKPYY) Stock Be Helped By Pursuit of $15 Billion in U.S. Deals?

Will Takeda Pharmaceutical (TKPYY) Stock Be Helped By Pursuit of $15 Billion in U.S. Deals?

Takeda Pharmaceuticals (TKPYY) CEO Christophe Weber said the company is exploring deals outside of Japan, particularly in the U.S.

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.

Takeda And The Crohn's & Colitis Foundation Of America Partner To Introduce 'IBD Unmasked' A First-of-its-Kind Awareness Campaign

Takeda And The Crohn's & Colitis Foundation Of America Partner To Introduce 'IBD Unmasked' A First-of-its-Kind Awareness Campaign

Aims to empower patients with inflammatory bowel disease through unique, Marvel Custom Solutions-illustrated stories featuring a Super Hero with IBD

Takeda Licenses Global Rights To Theravance Biopharma's TD-8954, A Novel 5-HT4 Agonist And Motility Agent For Gastrointestinal Motility Disorders

Takeda Licenses Global Rights To Theravance Biopharma's TD-8954, A Novel 5-HT4 Agonist And Motility Agent For Gastrointestinal Motility Disorders

Deal Provides Takeda Global Rights to Selective 5-HT4 Agonist; Highlights Takeda's Commitment to Gastroenterology as a Core Therapeutic Area

Takeda To Present New Data At The American Diabetes Association's 76th Scientific Sessions

Takeda To Present New Data At The American Diabetes Association's 76th Scientific Sessions

Eight abstract presentations include new analyses from the EXAMINE trial and real-world databases

Roivant Sciences And Takeda Launch Myovant Sciences To Develop Innovative Therapeutics For Women's Health And Prostate Cancer

Roivant Sciences And Takeda Launch Myovant Sciences To Develop Innovative Therapeutics For Women's Health And Prostate Cancer

- Myovant to conduct global phase 3 programs of relugolix, a potential best-in-class GnRH antagonist for the treatment of uterine fibroids, endometriosis and prostate cancer

Stocks Inch Higher as Yellen Hints at Summer Rate Hike

Stocks Inch Higher as Yellen Hints at Summer Rate Hike

Stocks inch higher by mid-afternoon Friday as Federal Reserve Chair Janet Yellen suggest the central bank could implement another rate hike this summer.

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.

Takeda Pharmaceuticals U.S.A., Inc. Announces Plans To Transform Business, Enhancing Value For Patients

Takeda Pharmaceuticals U.S.A., Inc. Announces Plans To Transform Business, Enhancing Value For Patients

Moves to Strengthen Portfolio Focus, Transfer Rights for CONTRAVE® and Invest in Recent Launches in United States

Orexigen And Takeda Jointly Announce Orexigen's Acquisition Of All Rights To CONTRAVE® In The United States

Orexigen And Takeda Jointly Announce Orexigen's Acquisition Of All Rights To CONTRAVE® In The United States

Acquisition provides Orexigen ownership of CONTRAVE in nearly all major global markets

FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)

FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)

New melt in your mouth tablet for appropriate adult patients with heartburn associated with Gastroesophageal Reflux Disease (GERD)

Tourmaline Fact Sheet

Tourmaline Fact Sheet

Takeda Pharmaceutical Company Limited ( TSE: 4502) today announced that the U.